Julie Park
St. Jude Children's Research Hospital · New Approaches to Neuroblastoma Treatment (NANT) · COG Phase I Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Julie Park as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:56 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07428993 · Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk OsteosarcomaSt. Jude Children's Research Hospital · recruiting · Pediatric Osteosarcoma · principal investigator
- Ph1NCT01208454 · Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent NeuroblastomaNational Cancer Institute (NCI) · completed · Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma · principal investigator
- Ph1NCT00622414 · Aflibercept in Treating Young Patients With Relapsed or Refractory Solid TumorsNational Cancer Institute (NCI) · completed · Unspecified Childhood Solid Tumor, Protocol Specific · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Translational, statistical, and clinical trials coreP01CA217959 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2019 to 2026 · $607,725 awarded in 2026Same name and institution; not confirmed by an ID
- Accelerate cellular immunotherapy development for treatment of life-threatening childhood disordersU01TR002487 · NCATS · SEATTLE CHILDREN'S HOSPITAL · fiscal years 2018 to 2022 · $1,395,617 awarded in 2022Same name and institution; not confirmed by an ID
- Novel Therapies for High-Risk NeuroblastomaK23CA087058 · NCI · SEATTLE CHILDREN'S HOSPITAL · fiscal years 2002 to 2006 · $131,220 awarded in 2006Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NATURAL KILLER CELL BASED IMMUNOTHERAPYP01CA081403 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI ROBERT Charles SEEGER · fiscal years 2000 to 2014Named on NCT01208454
- Children's Oncology Group Phase 1 / Pilot ConsortiumU01CA097452 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI SUSAN M. BLANEY · fiscal years 2002 to 2011Named on NCT00622414
Most cited trial papers
Clinical-trial papers with this author name in osteosarcoma, ranked by citations from NIH iCite, fetched 2026-11-12 10:56 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.J Immunother Cancer · 2017105 citationsRCR 3.4
- The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF.J Korean Med Sci · 20009 citationsRCR 0.2